公开(公告)号：US20170010272A1

公开(公告)日：2017-01-12

申请号：US15119519

申请日：2015-02-18

Applicant: STC, UNM

Inventor： Graham Timmins ,  Seong Won Choi ,  Louis Pete A. Silks

IPC: G01N33/58

CPC classification number: G01N33/58 ,  A61K49/0004 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2458/15 ,  G01N2800/52

Abstract: In one embodiment, the invention provides methods of identifying the sensitivity and resistance to therapeutic drug regimens in a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering (1) isotopically labeled Pretomanid and/or Delaminid, or (2) isotopically labeled ethionamide and/or prothionamide, or (3) isotopically labeled pyrazinamide, or (4) isotopically-labeled isoniazid to the subject and thereafter measuring levels in a subject-derived sample of one or more isotopically-labeled markers corresponding to Mycobacterium-actiwated drug metabolites or degradation products, wherein the absence of detectable levels of Mycobacterium-activated drug metabolites or degradation products indicates either that the subject does not suffer from a Mycobacterium infection or suffers from a Mycobacterium infection which is resistant to treatment with the administered drug regimen.

Abstract translation: 在一个实施方案中，本发明提供鉴定患有或疑似患有分枝杆菌感染的受试者的治疗药物方案的敏感性和抗性的方法，所述方法包括施用（1）同位素标记的假单胞菌素和/或 （2）同位素标记的乙硫氨酰胺和/或丙硫氨酰胺，或（3）同位素标记的吡嗪酰胺或（4）同位素标记的异烟肼，然后测定受试者衍生的样品中一种或多种同位素标记 对应于分枝杆菌活化的药物代谢物或降解产物的标记，其中不存在可检测水平的分枝杆菌激活的药物代谢物或降解产物表明受试者不患有分枝杆菌感染或遭受耐受治疗的分枝杆菌感染 与施用的药物方案。